

OriGene Technologies, Inc.

9620 Medical Center Dr., Suite 200, Rockville, MD 20850 Phone: 1.888.267.4436 Fax: 301-340-9254 Email: techsupport@origene.com Web: www.origene.com

Product Information

HSV-1 IgG ELISA kit

Catalog Number: EA100946 Storage Temperature: 2 – 8°C

Instruction for Use

Intended Use

The HSV-1 IgG ELISA Kit is intended for the detection of IgG antibody to HSV-1 in human serum or plasma.

Background

HSV-1 and 2 are virtually identical, sharing approximately 50% of their DNA and have over 80% of common antigens. Both types infect the body's mucosal surfaces, usually the mouth or genitals, and then establish latency in the nervous system. For both types, at least two-thirds of infected people have no symptoms, or symptoms too mild to notice. However, both types can recur and spread even when no symptoms are present. By the time they're teenagers or young adults, about 50% of Americans have HSV-1 antibodies in their blood. By the time they are over age 50, some 80-90% of Americans has HSV-1 antibodies. By comparison, almost all HSV-2 is encountered after childhood, when people become sexually active. HSV type 1 is the cause of most orofacial herpes and HSV encephalitis; type 2 is the primary cause of initial and recurrent genital herpes and neonatal HSV. Reactivation of latent HSV infection is a frequent complication of immunosuppression due to cancer, transplantation and AIDS. Asymptomatic genital shedding of HSV-2 is more common than HSV-1 and occurs more frequently during the first 3 months after acquisition of primary type 2 disease than during later periods. The presence of HSV IgG antibody is indicative of previous exposure A significant increases in HSV IgG is an indicative of reactivation, current or recent infection. IgM antibody is present after primary HSV infection.

Principle of the Test

Diluted patient serum is added to wells coated with purified antigen. IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample.

Components

	MATERIALS PROVIDED	96 Tests
1.	Microwells coated with HSV-1 antigen	12x8x1
2.	Sample Diluent: 1 bottle (ready to use)	22 ml
3.	Calibrator: 1 Vial (ready to use)	1ml
4.	Positive Control: 1 vial (ready to use)	1ml



OriGene Technologies, Inc.

5.	Negative Control: 1 vial (ready to use)	1ml
6.	Enzyme conjugate: 1 bottle (ready to use)	12ml
7.	TMB Substrate: 1 bottle (ready to use)	12ml
8.	Stop Solution: 1 bottle (ready to use)	12ml
9.	Wash concentrate 20X: 1 bottle	25ml

Materials and Equipment Required but Not Provided

- 1. Distilled or deionized water
- 2. Precision pipettes
- 3. Disposable pipette tips
- 4. ELISA reader capable of reading absorbance at 450nm
- 5. Absorbance paper or paper towel

Disclaimer

This product is for research use only and not intended for diagnostic procedures.

Specimen Collection and Preparation

- 1. Collect blood specimens and separate the serum.
- 2. Specimens may be refrigerated at 2–8°C for up to seven days or frozen for up to six months. Avoid repetitive freezing and thawing.

Reagent Preparation

1. Prepare 1X Wash buffer by adding Wash Concentrate (25 ml, 20X) to 475 ml of distilled or deionized water. Store at room temperature (18-26°C).

Assay Procedure

- Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (18-26°C). Gently mix all reagents before use
- The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed
- It is recommended that standards, control and serum samples be run in duplicate
- Do not use sodium azide as preservative. Sodium azide inhibits HRP enzyme activities
- 1. Place the desired number of coated strips into the holder.
- 2. Negative control, positive control, and calibrator are ready to use. Prepare 1:21 dilution of test samples, by adding 10 µl of the sample to 200 µl of sample diluent. Mix well.
- 3. Dispense 100 µl of diluted sera, calibrator and controls into the appropriate wells. For the reagent blank, dispense 100 µl sample diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 20 minutes at room temperature.
- 4. Remove liquid from all wells. Wash wells three times with 300 μl of 1X wash buffer. Blot on absorbance paper or paper towel.
- 5. Dispense 100 µl l of enzyme conjugate to each well and incubate for 20 minutes at room temperature.
- 6. Remove enzyme conjugate from all wells. Wash wells three times with 300 μl of 1X wash buffer. Blot on absorbance paper or paper towel.
- 7. Dispense 100 μl of TMB substrate and incubate for 10 minutes at room temperature. Add 100 μl of stop solution.

8. Read O.D. at 450 nm using ELISA reader within 15 min. A dual wavelength is recommended with reference filter of 600-650 nm

Calculation of Results

- 1. Check Calibrator Factor (CF) value on the calibrator bottle. This value might vary from lot to lot. Make sure you check the value on every kit.
- 2. Calculate the cut-off value: Calibrator OD x Calibrator Factor (CF).
- 3. Calculate the Ab (Antibody) Index of each determination by dividing the O.D. value of each sample by cutoff value.

Example of a Standard Curve

Calibrator mean OD = 0.8Calibrator Factor (CF) = 0.5Cut-off Value = $0.8 \times 0.5 = 0.400$ Positive control O.D. = 1.2Ab Index = 1.2 / 0.4 = 3Patient sample O.D. = 1.6Ab Index = 1.6 / 0.4 = 4.0

Quality Control

The test run may be considered valid provided the following criteria are met:

- 1. If the O.D. of the Calibrator should be greater than 0.250.
- 2. The Ab index for Negative control should be less than 0.9.
- 3. The Ab index for Positive control should be greater than 1.2.

Interpretation

The following is intended as a guide to interpretation of HSV-1 IgG test results; each laboratory is encouraged to establish its own criteria for test interpretation based on sample populations encountered.

- Antibody Index Interpretation
 - <0.9 No detectable antibody to HSV-1 IgG by ELISA
 - o 0.9-1.1 Borderline positive. Follow-up testing is recommended if clinically indicated.
 - >1.1 Detectable antibody to HSV-1 IgG by ELISA

• Converting of Ab Index to IU/mL

- As an option, Ab index may be converted to IU/ml by multiplying Ab index by 100. IU/ml values may then be interpreted as follows:
 - <90 IU/ml
 No detectable IgG antibody to HSV-1 by ELISA
 - o 90-110 IU/ml Borderline positive. Follow-up testing is recommended if clinically indicated.
 - > 110 IU/ml Detectable IgG antibody to HSV-1 by ELISA

References

- 1. Langeland N; Haarr L; Mhalu F. Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania. Int J STD AIDS 1998;9(2):104-7.
- Markoulatos P; Labropoulou V; Kordossi A; Krikelis V; Spyrou N; Moncany ML. A combined indirect ELISA and immunoblotting for the detection of intrathecal herpes simplex virus IgG antibody synthesis in patients with herpes simplex virus encephalitis. J Clin Lab Anal 1995;9(5):325-33.



OriGene Technologies, Inc.

- Markoulatos P; Fountoucidou P; Marinakis G; Krikelis V; Spyrou N; Vamvakopoulos N; Moncany ML. Clear detection and typing of herpes simplex virus types 1 and 2 by an indirect ELISA assay: comparison with three different combined methods--capture ELISA, restriction enzymes, and polymerase chain reaction. J Clin Lab Anal 1997; 11(3):146-53.
- 4. Herbert AM; Bagg J; Walker DM; Davies KJ; Westmoreland D. Seroepidemiology of herpes virus infections among dental personnel. J Dent 1995;23(6):339-42.
- Goodyear HM; McLeish P; Randall S; Buchan A; Skinner GR; Winther M; Rolland J; Morgan G; Harper JI. Immunological studies of herpes simplex virus infection in children with atopic eczema. Br J Dermatol 1996;134(1):85-93.

Version 3, last updated October 18, 2015